Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, ibalizumab (Trogarzo®) cannot be endorsed for use within NHS Wales for use in combination with other antiretroviral(s) for the treatment of adults infected with multidrug-resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen. This product is currently not marketed in the UK. |
||
|
||
Medicine details |
||
| Medicine name | ibalizumab (Trogarzo®) | |
| Formulation | 200 mg concentrate for solution for infusion | |
| Reference number | 3375 | |
| Indication | For use in combination with other antiretroviral(s) for the treatment of adults infected with multidrug-resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen |
|
| Company | Theratechnologies Inc | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 16/06/2020 | |
| Further information This product is currently not marketed in the UK. |
||